Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Eron, Joseph J

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. [electronic resource] - The Journal of infectious diseases Mar 2013 - 740-8 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1537-6613

10.1093/infdis/jis750 doi


Adult
Aged
Anti-HIV Agents--administration & dosage
Antiretroviral Therapy, Highly Active--methods
Drug Resistance, Viral
Female
HIV Infections--drug therapy
HIV-1--drug effects
Heterocyclic Compounds, 3-Ring--administration & dosage
Humans
Male
Middle Aged
Oxazines
Pilot Projects
Piperazines
Plasma--virology
Pyridones
Pyrrolidinones--pharmacology
RNA, Viral--blood
Raltegravir Potassium
Treatment Outcome
Viral Load
Young Adult